Azacitidine

Drug Profile

Azacitidine

Alternative Names: 5-azacytidine; Aza-C; Azacytidine; CC-486; Ladakamycin; NS-17; NSC-102816; U-18496; Vidaza

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pharmacia Corporation
  • Developer Australasian Leukaemia & Lymphoma Group; Celgene Corporation; H. Lee Moffitt Cancer Center and Research Institute; Karolinska University Hospital; Nippon Shinyaku; Pfizer; University of Colorado at Denver; University of Kansas Medical Center; University of Texas M. D. Anderson Cancer Center; University of Utah; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Breast cancer; Leukaemia; Nasopharyngeal cancer; Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Diffuse large B cell lymphoma; Renal cancer; Solid tumours
  • Phase I Lymphoma; Multiple myeloma

Most Recent Events

  • 30 Jun 2017 Celgene completes enrolment in the phase III QUAZAR trial in Acute myeloid leukaemia in USA, Canada, Australia, South Korea, Belgium, Germany, Austria, Italy, Portugal, Lithuania, Spain, Finland, Czech Republic and Israel
  • 13 Jun 2017 Columbia University plans a phase I/II trial for T-cell lymphoma (Combination therapy) in USA (NCT03161223)
  • 07 Jun 2017 University of Pittsburgh, Incyte Corporation and Merck Sharp & Dohme plan a phase Ib/II trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) (NCT03182894)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top